Ignite Creation Date:
2024-05-06 @ 5:44 PM
Last Modification Date:
2024-10-26 @ 2:35 PM
Study NCT ID:
NCT05418309
Status:
UNKNOWN
Last Update Posted:
2022-06-14
First Post:
2022-06-09
Brief Title:
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable a Multi-center Study
Sponsor:
Tianjin Medical University Second Hospital
Organization:
Tianjin Medical University Second Hospital
Conditions & Keywords Data
Conditions:
| Name |
|---|
| High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma |
Keywords:
| Name | View |
|---|---|
| Tislelizumab Nab-Paclitaxe | View |